Premium Istradefylline API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Istradefylline (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Adenosine A2A Receptor Antagonist

Indications: Parkinson's Disease (Adjunct treatment for "off" episodes)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Istradefylline distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Istradefylline is a highly selective, non-dopaminergic small-molecule Active Pharmaceutical Ingredient (API). In central nervous system (CNS) pharmacology, it is classified as an adenosine A2A receptor antagonist. For pharmaceutical manufacturers developing advanced neurology portfolios, this API provides a critical, alternative mechanistic pathway for managing neurodegenerative motor control disorders.

Unlike standard Parkinson’s disease medications (such as levodopa or dopamine agonists) that directly replace or mimic dopamine, Istradefylline operates outside the dopaminergic system. At the neurochemical level, it functions as a potent, selective antagonist at the adenosine A2A receptors, which are densely localized in the basal ganglia—the region of the brain responsible for motor control.

In patients with Parkinson’s disease, the depletion of dopamine leads to an overactivity of the indirect output pathway (the striatopallidal pathway). Adenosine A2A receptors stimulate this exact pathway. By competitively blocking these receptors, Istradefylline reduces this overactivity, thereby restoring a functional balance in the basal ganglia and improving motor function.

For pharmaceutical formulation scientists, integrating this API enables the production of a highly effective adjunct therapeutic. In finished pharmaceutical products, Istradefylline is typically formulated into 20 mg and 40 mg oral solid dosage forms (tablets) intended to be prescribed alongside standard levodopa/carbidopa regimens.

Sourcing Istradefylline in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced CNS formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty neurological APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. As a dedicated pharmaceutical raw material supplier, sourcing Istradefylline Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether your facility requires a small R&D batch or is executing a high-volume Istradefylline api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during dry blending and direct compression processes.

Technical Specifications for QA & R&D

The Istradefylline API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (also referred to as an 8-styrylxanthine derivative)
• CAS Number: 155270-99-8
• Appearance: Pale yellow to light yellow-green crystalline solid powder
• Molecular Formula: C20H24N4O4
• Molecular Weight: 384.43 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Istradefylline is a pharmacologically active CNS compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor and maintain specific environmental controls to protect the API structure.

• Storage Conditions (Light Sensitivity): Store the raw API powder in securely closed, strictly light-resistant containers. Due to its chemical structure (containing a styryl double bond), Istradefylline is susceptible to photoisomerization (converting from the active E-isomer to the inactive Z-isomer) upon exposure to light. Maintain climate-controlled conditions, strictly protected from UV and visible light, excessive heat, and humidity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, micronization, milling, and blending stages must be executed within localized exhaust ventilation systems (under amber or actinic lighting) to prevent the inhalation of airborne particulates and API photo-degradation.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.